Format

Send to

Choose Destination
J Clin Endocrinol Metab. 2019 Feb 1;104(2):423-432. doi: 10.1210/jc.2018-01452.

Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill.

Author information

1
Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
2
Los Angeles Biomedical Research Institute and Harbor UCLA Medical Center, Torrance, California.
3
Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
4
University of California, Los Angeles, Los Angeles, California.
5
Health Decisions, Durham, North Carolina.
6
National Institutes of Health - National Institute of Child Health and Human Development, Bethesda, Maryland.

Abstract

Context:

Dimethandrolone (DMA) has androgenic and progestational activity. Single oral doses of DMA undecanoate (DMAU) were well tolerated and reversibly suppressed serum LH and testosterone (T) in men.

Objective:

Assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of oral DMAU.

Design:

Double-blind, randomized, placebo-controlled study.

Setting:

Two academic medical centers.

Participants:

Healthy men (18 to 50 years).

Interventions:

One hundred men received DMAU [0, 100, 200, or 400 mg, formulated in castor oil/benzyl benzoate (C) or powder (P)] for 28 days. Subjects underwent 24-hour PK sampling on days 1 and 28 and twice weekly ambulatory visits throughout treatment.

Main Outcome Measures:

Primary outcomes were safety and tolerability parameters (vitals, laboratory data, mood, and sexual function scores) and adverse events. Secondary outcomes were drug PK profiles and PD effects (serum LH, FSH, and sex hormones).

Results:

Eighty-two subjects completed the study and were included in the analysis. There were no serious adverse events. No clinically significant changes developed in safety laboratory parameters. A significant dose effect was seen for weight, hematocrit, high-density lipoprotein cholesterol, corrected QT interval, and sexual desire. Serum 24-hour average concentrations of DMAU and DMA showed dose-related increases (P < 0.001). All six subjects in the P400 group and 12 of 13 subjects in the C400 group achieved marked suppression of LH and FSH (<1.0 IU/L) and serum T (<50 ng/dL).

Conclusions:

Daily oral administration of DMAU for 28 days in healthy men is well tolerated. Doses of ≥200 mg markedly suppress serum T, LH, and FSH. These results support further testing of DMAU as a male contraceptive.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01382069.

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center